The induction characteristics of etomidate, a new i.v. hypnotic agent, were studied in 400 patients. Two hundred were premedicated with atropine and anaesthesia was induced with 0.2, 0.25, 0.3 or 0.35 mg/kg of etomidate. The remainder received one of four standard premedications and anaesthesia was induced with etomidate 0.3 mg/kg. Involuntary muscle movements occurred in more than 60% of patients receiving atropine alone. The frequency was reduced in the second group, but remained unacceptable in over 8% of patients. The incidence of other excitatory phenomena, such as cough and hiccup, was 10% approximately. Cardiovascular changes were minimal and no serious allergic phenomena were observed. Nausea and vomiting occurred after surgery in up to 30% of patients and was unrelated to the dose of etomidate or to premedication. Pain on injection occurred in up to 80% of patients when the drug was injected into small peripheral veins and occurred in more than 7% when using more proximal veins.
Etomidate (R-(+)-ethyl-l-(pentylethyl) lH-imidazole-5-carboxylate sulphate ( fig. 1) ) is a recently introduced i.v. induction agent. The drug is watersoluble and is presented as a 0.15% solution of pH 3 units. Animal work by Janssen and colleagues (1971) suggested that etomidate caused rapid induction of anaesthesia and had a wider margin of safety than thiopentone, methohexitone and propanidid.
Preliminary work in man by Doenicke, Kugler and others (1973) and Doenicke, Wagner and Beetz (1973) suggested that, at a dose of 0.3 mg/kg, etomidate would induce hypnosis with minimal cardiorespiratory effects. They observed that the drug caused involuntary movements, which may be severe, but their incidence could be reduced by diazepam. Morgan, Lumley and Whitwam (1975) confirmed that the optimum dose of etomidate was approximately 0.3 mg/kg, and observed a high incidence of involuntary muscle movement.
The purpose of the present study was to investigate the effect of the dose of etomidate and premedication on its induction characteristics. 
METHODS
Etomidate was used as a single i.v. induction agent for non-emergency surgery, excluding cardiothoracic surgery and surgery in pregnancy. The following observations were made: (1) Involuntary muscle movements, which were classified as (a) severe, resembling a generalized convulsion, (b) moderate, when there was contraction of a large group of muscles or less severe generalized muscle activity, and (c) mild, when restricted to slight twitching involving one or more limbs which did not interfere with induction.
(2) Respiratory disturbances such as cough, hiccup and laryngospasm. (3) Pulse rate and arterial pressure (by palpatation) at 1-min intervals for 5 min. (4) Any evidence of an allergic reaction. (5) Because of the increase in muscle tone associated with etomidate, serum potassium concentrations were measured in 40 consecutive patients who were premedicated with atropine only. A control sample of venous blood was taken, and further samples were taken at 1, 3, 5 and 10 min after the administration of etomidate. The 1-min sample was taken before any other agents were given. In 20 of these patients, suxamethonium 1 mg/kg was given immediately following the 1-min sample. Serum potassium estimations were made, using serum from clotted blood, with an EEL 150 Clinical Flame Photometer (Evans, Electroselenium, Halstead, Essex).
Varying dose. Two hundred patients received atropine 0.6 mg i.m. 1 hr before operation. They were allocated randomly to receive 0.2, 0.25, 0.3 and 0.35 mg/kg of etomidate, which was injected i.v. during a period of 30 sec.
Premedication. A further 200 patients were allocated randomly to receive one of the following drug combinations 1 hr before operation: (1) Papaveretum 10-20 mg and hyoscine 0.2-0.4 mg; (2) pethidine 50-100 mg and atropine 0.6 mg; (3) pethidine 50-100 mg, promethazine 12.5-25 mg and atropine 0.6 mg; (4) diazepam 10-20 mg orally and atropine 0.6 mg i.m. The doses were varied according to the individual's requirements and all these patients received, for induction of anaesthesia, etomidate 0.3 mg/kg.
After induction, in both groups, anaesthesia was maintained with nitrous oxide in oxygen, other agents being administered according to the type of operation. Each patient was visited on the day following the operation to ascertain the occurrence of nausea and vomiting, and thrombophlebitis at the site of injection.
RESULTS
The age, weight and physical status of the 400 patients in the study are shown in (table III) . Hiccup occurred in a small number of patients but was not troublesome. The duration of clinically observed apnoea was prolonged following etomidate 0.35 mg/kg and in those patients who were given papaveretum and hyoscine. The frequency of apnoea was not affected markedly by premedication. Hyperventilation and coughing during induction were not common. Laryngospasm occurred in two patients; it was mild in both and disappeared rapidly.
Cardiovascular effects. The changes in pulse rate and arterial pressure at 1 min after the administration of etomidate, following which other drugs were administered, are shown in table IV. Severe hypotension did not occur and the observed reductions in arterial pressure never required treatment. The most obvious cardiovascular effect was a greater increase in pulse rate in the patients who received atropine alone Sensitivity reactions. One patient developed an erythematous rash but showed no evidence of serious allergic phenomena such as hypotension or bronchoconstriction. In another three patients a similar rash was observed following either suxamethonium or tubocurarine.
Pain on injection. Eighty-one per cent of patients complained of pain on injection when this was made into small peripheral veins, such as the dorsum of the hand. When injection was made into larger veins on the forearm or at the elbow, the frequency of pain was 44% and 8%, respectively.
Serum potassium (table V) . The individual variation in duplicate analyses was no greater than 0.1 m-mol/ litre. When etomidate was used alone, the serum potassium concentration at 3 min in those patients who exhibited no or mild muscle movement decreased by about 5% from the control value, whereas in those patients in whom more severe movements occurred, there was an increase of 3%. The changes in serum potassium are shown in table V; none is statistically significant. Even when suxamethonium was administered, moderate or severe muscle movement was observed following induction with etomidate. The mean serum potassium concentration increased by a maximum of 6% (0.23 m-mol/litre), and this was not significant CP>0.05).
Postoperative sequelae (table VI) . The dose of etomidate and the premedication had little effect on the occurrence of nausea and vomiting, the latter being slightly more common in those who had received atropine only (28% compared with 24%) and least in those premedicated with diazepam (16%), but this was not statistically significant (P> 0.1). Mild thrombophlebitis, which cleared rapidly, occurred after operation in one patient.
DISCUSSION
In patients premedicated with atropine alone, a single induction dose of etomidate was associated with a high frequency of involuntary muscle movement (table II) , which subsided rapidly. The combination of intermittent etomidate with nitrous oxide alone to maintain anaesthesia was associated with a persistent increase in muscle tone and involuntary movements and was impractical.
At the highest dose of etomidate (0.35 mg/kg), the frequency of severe and moderate movements was not significantly higher than at the other doses. The most satisfactory dose would appear to be in the region of 0.3 mg/kg, as suggested by Doenicke and others (Doenicke, Kugler et al., 1973; Doenicke, Wagner and Beetz, 1973) , since this provides an adequate duration of hypnosis (Morgan, Lumley and Whitwam, 1975) , while a larger dose leads to an increase in the proportion of unacceptable inductions.
In many patients the appearance of excitatory phenomena appeared to be evoked reflexly by stimulation such as results from insertion of an i.v. cannula and the measurement of arterial pressure. The occurrence of muscle movement was reduced markedly by the inclusion of premedicant drugs other than atropine alone (P<0.01). Diazepam has been reported to reduce the incidence of these phenomena (Doenicke et al., 1973) and this was confirmed in the present study. The inclusion of opiates in the premedication was associated with an acceptable induction (either no or mild muscle movements) in more than 90% of patients. A reduction of involuntary movements on induction of anaesthesia following opiate premedication has been observed previously with methohexitone, propanidid and Althesin (Dundee and Wyant, 1974) .
The administration of suxamethonium is associated with an increase in plasma potassium of the order of 5-6% (Stovner, Endresen and Bjelke, 1972) , which may increase to a greater extent in patients suffering from burns or who are in renal failure. Intravenous induction agents, such as methohexitone, tend to reduce the concentration of potassium in the plasma (Bali and Dundee, 1974) , and this was the case also, in the present study, in patients who did not exhibit marked muscle movement after the administration of etomidate. However, the appearance of moderate and severe muscle movements reversed this trend and in this group of patients etomidate appears to behave in a manner different from other agents. Where moderate and severe muscle movements occurred following etomidate, in association with the administration of suxamethonium, there was an increase in the plasma potassium concentration of 6% which was similar to that reported by Stovner and colleagues (1972) , but in the present study the groups of patients were relatively small and the observed changes were not statistically significant.
Pain during injection was very common when small peripheral veins were used and the drug should be administered to large veins on the forearm. Rowlands (1969) found that the addition of lignocaine to methohexitone solutions reduced the incidence of pain and discomfort from 10% to 1 %, and it may be that a similar technique would be successful with etomidate.
The incidence of cough, hiccup and laryngospasm was small and was not dose-related. The incidence and duration of clinically observed apnoea were related to the dose of etomidate, but the incidence was less frequent than has been reported following the administration of thiopentone, methohexitone and Althesin (Whitwam, 1962; Hall, Whitwam and Morgan, 1973 ).
Etomidate appears to cause minimal cardiovascular effects. In the majority of patients there were only small changes in pulse rate and arterial pressure, and severe hypotension did not occur. Previously, Morgan, Lumley and Whitwam (1975) noted a slight but significant decrease in systolic arterial pressure from the control values during a 5-min period, with no change in pulse rate.
Anaphylactic reactions are being reported more commonly in association with the use of i.v. induction agents. Although four patients in this series developed a rash following etomidate, the cause was uncertain, and there was no associated hypotension or bronchospasm. Doenicke, Lorenz and others (1973) have demonstrated that etomidate, unlike the other i.v. induction agents, does not cause histamine release and this could be a significant advantage of the drug.
In this study, the occurrence of nausea and vomiting appeared to be unrelated to the dose of etomidate or to the premedication, and was only slightly greater than that reported for thiopentone, methohexitone and propanidid (Clarke et al., 1971) . Only one of the 400 patients developed thrombophlebitis, which is less than the frequency occurring with the other drugs mentioned above (Carson et al., 1972) .
This study was not concerned primarily with recovery following etomidate. However, unlike the barbiturates whose short duration of action is a result of redistribution (Price et al., 1960 ), etomidate appears to be hydrolysed, which could explain its short duration of action, and in this respect it is similar to propanidid. In the present study, following short procedures, recovery from anaesthesia was rapid and there was no "hangover".
The two major disadvantages of etomidate are pain on injection and muscle movement. When compared with methohexitone (Dundee et al., 1961) , the incidence of these muscle movements following the administration of etomidate is influenced less by the dose of the drug and more by premedication. 
EFECTOS DE LAS DOSIS Y PREMEDICACION SOBRE LAS COMPLICACIONES DE LA INDUCCION CON ETOMIDATO

SUMARIO
Se estudiaron en 400 pacientes las caracteristicas de inducci6n del etomidato, un nuevo agente hipnotico. Doscientos fueron premedicados con atropina y se provoco la anestesia con 0,2, 0,25, 0,3 6 0,35 mg/kg de etomidato. El resto recibio una de cuatro premedicaciones normales y se provoco la anestesia con 0,3 mg/kg de etomidato. Se produjeron movimientos musculares involuntarios en mas del 60% de pacientes que recibieron solo atropina. La produjeron nauseas y vomitos despues de intervention frecuencia se redujo en el segundo grupo, pero pennanecio quirurgica en hasta el 30% de los pacientes. Se observo inaceptable en mas del 8% de los pacientes. La incidencia de dolor en la inyeccion en hasta 80% de los pacientes cuando otros fenomenos excitables, tales como la tos y el hipo fue se inyecto la droga en pequefias venas perifericas y se aproximadamente del 10%. Los cambios cardiovasculares produjo en mas del 7% cuando se usaron mas venas fueron minimos y no se observaron fen6menos alergicos. Se proximales.
